A novel strategy for modulation of MDSC to enhance cancer immunotherapy.

abstract：:Removing less potent T cell subsets as well as poorly- or non-engineered cells can optimize effectiveness of engineered T cell therapy against cancer. We have recently described a novel, GMP-ready method for the purification of engineered immune cells that might further boost the clinical success of cancer immunothera...

journal_title：Oncoimmunology

authors： Kierkels GJ,Straetemans T,de Witte MA,Kuball J

更新日期：2015-08-27 00:00:00

abstract：:The generation and loading of dendritic cells (DC) ex-vivo for tumor vaccination purposes is laborious and costly. Direct intradermal (i.d.) administration of tumor-associated antigens could be an attractive alternative approach, provided that efficient uptake and cross-presentation by appropriately activated skin DCs...

journal_title：Oncoimmunology

authors： Ruben JM,Bontkes HJ,Westers TM,Hooijberg E,Ossenkoppele GJ,van de Loosdrecht AA,de Gruijl TD

更新日期：2014-07-03 00:00:00

abstract：:PD-1 engagement on the surface of effector T cells strongly suppresses their cytotoxic function, which constitutes a major obstacle for T cell-mediated anti-tumor activities. Surprisingly, PD-1 is strongly upregulated in T cells, engaging its ligand PD-L1 during antigen presentation. However, our recent published data...

journal_title：Oncoimmunology

authors： Karwacz K,Arce F,Bricogne C,Kochan G,Escors D

更新日期：2012-01-01 00:00:00

abstract：:Immunotherapy by chimeric antigen receptor (CAR)-modified T-cells has shown unprecedented clinical efficacy for hematological malignancies. Recently two CAR T-cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) were approved by the US Food and Drug Administration and by the Europ...

journal_title：Oncoimmunology

authors： Alcantara M,Du Rusquec P,Romano E

更新日期：2020-06-10 00:00:00

abstract：:Recently, there has been a growing interest in the importance of stem cells (SCs) in the development/progression of gastric neoplasms. In this study, we performed a comprehensive analysis of different populations of bone-marrow-derived stem cells (BMSCs) in patients with various types of gastric malignancies, includin...

journal_title：Oncoimmunology

authors： Błogowski W,Zuba-Surma E,Sałata D,Budkowska M,Dołęgowska B,Starzyńska T

更新日期：2015-10-29 00:00:00

abstract：:CD69 is an early activation marker on the surface of T lymphocytes undergoing activation by cognate antigen. We observed intense expression of CD69 on tumor-infiltrating T-lymphocytes that reside in the hypoxic tumor microenvironment and hypothesized that CD69 could be, at least partially, under the control of the tra...

journal_title：Oncoimmunology

authors： Labiano S,Meléndez-Rodríguez F,Palazón A,Teijeira Á,Garasa S,Etxeberria I,Aznar MÁ,Sánchez-Paulete AR,Azpilikueta A,Bolaños E,Molina C,de la Fuente H,Maiso P,Sánchez-Madrid F,de Landázuri MO,Aragonés J,Melero I

更新日期：2017-01-19 00:00:00

abstract：:Oncolytic viruses (OVs) preferentially target and kill cancer cells without affecting healthy cells through a multi-modal mechanism of action. While historically the direct killing activity of OVs was considered the primary mode of action, initiation or augmentation of a host antitumor immune response is now considere...

journal_title：Oncoimmunology

authors： Davola ME,Mossman KL

更新日期：2019-03-28 00:00:00

abstract：:Graft-versus-host disease (GvHD) remains a significant impediment to allogeneic hematopoietic cell transplantation (HCT) success, necessitating studies focused on alleviating GvHD, while preserving the graft-versus-leukemia (GvL) effect. Based on our previous studies showing bendamustine with total body irradiation (B...

journal_title：Oncoimmunology

authors： Stokes J,Hoffman EA,Molina MS,Kummet N,Simpson RJ,Zeng Y,Katsanis E

更新日期：2020-04-30 00:00:00

abstract：:Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides spec...

journal_title：Oncoimmunology

authors： Pitt JM,Vétizou M,Gomperts Boneca I,Lepage P,Chamaillard M,Zitvogel L

更新日期：2016-02-18 00:00:00

abstract：:Prognosis of glioblastoma remains dismal, underscoring the need for novel therapies. Immunotherapy is generating promising results, but requires combination strategies to unlock its full potential. We investigated the immunomodulatory capacities of poly(I:C) on primary human glioblastoma cells and its combinatorial po...

journal_title：Oncoimmunology

authors： De Waele J,Marcq E,Van Audenaerde JR,Van Loenhout J,Deben C,Zwaenepoel K,Van de Kelft E,Van der Planken D,Menovsky T,Van den Bergh JM,Willemen Y,Pauwels P,Berneman ZN,Lardon F,Peeters M,Wouters A,Smits EL

更新日期：2017-12-12 00:00:00

abstract：:The benefits of anti-cancer agents extend beyond direct tumor killing. One aspect of cell death is the potential to release antigens that initiate adaptive immune responses. Here, a diffusion enhanced formulation, INT230-6, containing potent anti-cancer cytotoxic agents, was administered intratumorally into large (app...

journal_title：Oncoimmunology

authors： Bloom AC,Bender LH,Tiwary S,Pasquet L,Clark K,Jiang T,Xia Z,Morales-Kastresana A,Jones JC,Walters I,Terabe M,Berzofsky JA

更新日期：2019-07-16 00:00:00

abstract：:Successful cancer immunotherapy necessitates T cell proliferation and infiltration into tumor without exhaustion, a process closely links optimal maturation of dendritic cells (DC), and adjuvant promotes this process as an essential prerequisite. Poly(I:C) has contributed to adjuvant immunotherapy that evokes an antit...

journal_title：Oncoimmunology

authors： Azuma M,Takeda Y,Nakajima H,Sugiyama H,Ebihara T,Oshiumi H,Matsumoto M,Seya T

更新日期：2016-05-19 00:00:00

abstract：:We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM). Patients with relapsed/refractory solid tumors not amenable to standard therapy received solitomab as continuous IV infusion in a phase 1 dose-es...

journal_title：Oncoimmunology

authors： Kebenko M,Goebeler ME,Wolf M,Hasenburg A,Seggewiss-Bernhardt R,Ritter B,Rautenberg B,Atanackovic D,Kratzer A,Rottman JB,Friedrich M,Vieser E,Elm S,Patzak I,Wessiepe D,Stienen S,Fiedler W

更新日期：2018-04-18 00:00:00

abstract：:When naive mice receive short Zfra peptides via tail vein injections, they develop lifetime resistance to growth of many cancer xenografts, due to activation of a novel spleen memory Hyal-2+ CD3- CD19- Z lymphocyte. In vitro education of spleen cells with Zfra activates Z cell for conferring memory anticancer response...

journal_title：Oncoimmunology

authors： Su WP,Wang WJ,Sze CI,Chang NS

更新日期：2016-07-28 00:00:00

abstract：:MDR1 is an ATP-dependent transmembrane transporter primarily studied for its role in the detoxification of tissues and for its implication in resistance of tumor cells to chemotherapy treatment. Several studies also report on its expression on immune cells where it plays a protective role from xenobiotics and toxins. ...

journal_title：Oncoimmunology

authors： Bossennec M,Di Roio A,Caux C,Ménétrier-Caux C

更新日期：2018-09-06 00:00:00

abstract：:B cells are generally believed to operate as producers of high affinity antibodies to defend the body against microorganisms, whereas cellular cytotoxicity is considered as an exclusive prerogative of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). In conflict with this dogma, recent studies have demonst...

journal_title：Oncoimmunology

authors： Hagn M,Jahrsdörfer B

更新日期：2012-11-01 00:00:00

abstract：:Metastatic breast cancer remains an incurable disease. Most patients experience objective treatment responses associated with palliation of symptoms; however, progression inevitably occurs. Thus, there is an urgent need for innovative therapeutic strategies that may halt disease progression. Adoptive T-cell therapy is...

journal_title：Oncoimmunology

authors： Thakur A,Lum LG

更新日期：2015-07-15 00:00:00

abstract：:Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components. These changes can directly influence epitope presentation and t...

journal_title：Oncoimmunology

authors： Steinbach A,Winter J,Reuschenbach M,Blatnik R,Klevenz A,Bertrand M,Hoppe S,von Knebel Doeberitz M,Grabowska AK,Riemer AB

更新日期：2017-06-20 00:00:00

abstract：:Recent studies have proposed that tumor-specific tumor-infiltrating CD8+ T lymphocytes (CD8 TIL) can be classified into two main groups: "exhausted" TILs, characterized by high expression of the inhibitory receptors PD-1 and TIM-3 and lack of transcription factor 1 (Tcf1); and "memory-like" TILs, with self-renewal cap...

journal_title：Oncoimmunology

authors： Carmona SJ,Siddiqui I,Bilous M,Held W,Gfeller D

更新日期：2020-03-12 00:00:00

abstract：:Despite the clinical success of anti-PD1 antibody (α-PD1) therapy, the immune mechanisms contributing to the antineoplastic response remain unclear. Here, we describe novel aspects of the immune response involved in α-PD1-induced antitumor effects using an orthotopic Kras (G12D)/p53(R172H)/Pdx1-Cre (KPC) model of panc...

journal_title：Oncoimmunology

authors： D'Alincourt Salazar M,Manuel ER,Tsai W,D'Apuzzo M,Goldstein L,Blazar BR,Diamond DJ

更新日期：2016-03-16 00:00:00

abstract：:Regulatory T cells (Tregs) can prevent graft-vs.-host disease as induced by the infusion of donor lymphocytes to cancer patients, but often they also suppress therapeutic antitumor immunity. We discuss an exception to this phenomenon, exemplifying how the milieu provided by the bone marrow may neutralize Tregs to allo...

journal_title：Oncoimmunology

authors： Guichelaar T,Mutis T

更新日期：2013-07-01 00:00:00

abstract：:Low expression of RhoGDI2 is associated with poor outcome in cancer patients. In animal models, RhoGDI2 suppresses lung metastasis by reducing the expression of the proteoglycan versican, whose levels portend poor patient prognosis. Versican promotes metastasis through enhanced tumor migration and creation of an infla...

journal_title：Oncoimmunology

authors： Said N,Theodorescu D

更新日期：2012-10-01 00:00:00

abstract：:Recently, the study of microRNAs has expanded our knowledge of the fundamental processes of cancer biology and the underlying mechanisms behind tumor metastasis. Extensive research in the fields of microRNA and its novel mechanisms of actions against various cancers has more recently led to the trial of a first cancer...

journal_title：Oncoimmunology

authors： Park JH,Theodoratou E,Calin GA,Shin JI

更新日期：2016-09-09 00:00:00

abstract：:Interleukin (IL)-10 is a major cancer-related immunosuppressive factor, exhibiting a unique ability to hamper the maturation of dendritic cells (DCs). We have previously reported that IL-10 induces the conversion of activated, migratory CD1a+ DCs found in the human skin to CD14+CD141+ macrophage-like cells. Here, as a...

journal_title：Oncoimmunology

authors： Lindenberg JJ,van de Ven R,Lougheed SM,Zomer A,Santegoets SJ,Griffioen AW,Hooijberg E,van den Eertwegh AJ,Thijssen VL,Scheper RJ,Oosterhoff D,de Gruijl TD

更新日期：2013-04-01 00:00:00

abstract：:High-dose chemotherapy may kill not only tumor cells but also immunocytes, and frequently induces severe lymphocytopenia. On the other hand, patients who recover from the nadir maintain immunity against infection, suggesting the existence of an unknown memory T-cell population with stress resistance, long-living capac...

journal_title：Oncoimmunology

authors： Murata K,Tsukahara T,Emori M,Shibayama Y,Mizushima E,Matsumiya H,Yamashita K,Kaya M,Hirohashi Y,Kanaseki T,Kubo T,Himi T,Ichimiya S,Yamashita T,Sato N,Torigoe T

更新日期：2016-06-08 00:00:00

abstract：:The presence of tumor-infiltrating lymphocytes (TILs) is a strong prognostic parameter for local dissemination and overall survival in melanoma. Lymphocyte migration from blood into peripheral tissues is mainly regulated by vascular endothelium. However, the blood vessels and mechanisms governing the recruitment of TI...

journal_title：Oncoimmunology

authors： Martinet L,Le Guellec S,Filleron T,Lamant L,Meyer N,Rochaix P,Garrido I,Girard JP

更新日期：2012-09-01 00:00:00

abstract：:Analysis of PDL1 mRNA expression in ∼5,500 breast cancers showed PDL1 upregulation in 38% of basal tumors and 38% of inflammatory breast cancers (IBC). Upregulation, associated with signs of strong cytotoxic local immune response, was associated with a better survival in the basal or triple-negative subtypes, and with...

journal_title：Oncoimmunology

authors： Bertucci F,Finetti P,Birnbaum D,Mamessier E

更新日期：2015-08-31 00:00:00

abstract：:Interleukin-12 immune stimulation lacks efficacy in established solid tumor models. Disruption of tumor microenvironment homeostasis by low-dose cyclophosphamide prior to interleukin-12 gene therapy led to CD8+ T cell-driven established tumor rejection. This only takes place when inflammatory myeloid cells infiltrate ...

journal_title：Oncoimmunology

authors： Medina-Echeverz J,Berraondo P

更新日期：2012-01-01 00:00:00

abstract：:Recent findings from our laboratory provide the first indication that overexpression of Bcl-2 in Eµ-myc transgenic cells enhances tumor immunosurveillance by inducing NKG2D ligands. Initial evidence suggests that this model is relevant to human patients. Thus, antitumor therapies that target Bcl-2 harbor the risk of r...

journal_title：Oncoimmunology

authors： Putz EM,Schuster C,Sexl V

更新日期：2012-08-01 00:00:00

abstract：:Granulysin is a protein present in the granules of human cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, with cytolytic activity against microbes and tumors. Previous work demonstrated the therapeutic effect of intratumoral injection of recombinant granulysin using in vivo models of breast cancer and mult...

journal_title：Oncoimmunology

authors： Ibáñez-Pérez R,Guerrero-Ochoa P,Al-Wasaby S,Navarro R,Tapia-Galisteo A,De Miguel D,Gonzalo O,Conde B,Martínez-Lostao L,Hurtado-Guerrero R,Sanz L,Anel A

更新日期：2019-07-22 00:00:00